Do you want to read an article? Please log in or register.
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
Lung, Respiratory and Thoracic Cancer
RECOMMENDED
Related content
Lung, Respiratory and Thoracic Cancer
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)
Lung Cancer
Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H
doi: 10.1016/j.lungcan.2024.107968
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
Lung Cancer
Camidge DR, Sugawara S, Kondo M, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Kudou K, Asato T, Hupf B, Vranceanu F, Fram RJ, Ohe Y, Popat S
doi: 10.1016/j.lungcan.2025.108424
ASH 2024
Lymphoma
Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice
Lung, Respiratory and Thoracic Cancer
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
J Thorac Oncol
Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM
doi: 10.1016/j.jtho.2024.11.025
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Lung, Respiratory and Thoracic Cancer
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
Lung Cancer
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K
doi: 10.1016/j.lungcan.2025.108447
Lymphoma
Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL
Lung, Respiratory and Thoracic Cancer
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study
Transl Lung Cancer Res
Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L
doi: 10.21037/tlcr-24-881
RECOMMENDED
Breast Cancer
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Nakatani S, Hayashi T, Yamamoto K, Maeda H
doi: 10.1016/j.ctrv.2025.102923